Status:
COMPLETED
Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
Lead Sponsor:
GlaxoSmithKline
Conditions:
Type 2 Diabetes Mellitus
CV Risk
Eligibility:
All Genders
40-80 years
Brief Summary
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with diabetes type 2 that their physician has decided to prescribe AVANDIA for better control of their condition
- Have signed informed consent
- Exclusion Criteria:
- Patients with ALT \> 2.5x the normal value
- With heart failure symptoms
- With diagnosis of angina pectoris or stable angina demanding continuous treatment with nitrates
- With recent myocardial infarction (\<6 months)
- With severe renal disfunction
- Pregnant or lactating or planned to be pregnant during the study
- Under investigational drug treatment
- Alcoholic or drug abuser
Exclusion
Key Trial Info
Start Date :
March 1 2004
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT00648284
Start Date
March 1 2004
Last Update
October 15 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.